A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with
locally advanced or metastatic HER2 overexpressed biliary tract cancer who have failed
first-line chemotherapy.